In value discussions, few phrases carry more weight than “standard of care.”
It’s the benchmark, the reference point, and the foundation for comparative claims.
But in today’s market access environment, one uncomfortable reality is becoming harder to ignore:
Standard of care isn’t standard.
And when comparator assumptions don’t reflect how care is actually delivered, even strong evidence can fall flat.
The Illusion of a Single Standard
Clinical trials often define a comparator clearly and cleanly.
In practice, care delivery is anything but.
Across geographies, health systems, and payer types, treatment patterns vary:
- Some regions favor older, lower-cost therapies
- Others move quickly to novel agents
- Health systems may adopt internal pathways that override payer positioning
- Specialty centers may treat earlier or more aggressively
What appears uniform in a trial protocol may fragment in real-world care.
If your value story assumes uniform adoption of a comparator, it may already be misaligned.
Why Comparator Misalignment Matters
When comparator selection doesn’t reflect actual practice, it creates friction in payer evaluation:
- Budget impact models may appear unrealistic
- Cost offsets may not resonate
- Clinical differentiation may feel overstated
- Economic arguments may lose credibility
Payers aren’t only asking, “Is this better?”
They’re asking, “Better than what we’re actually using?”
That nuance matters.
The Health System Variable
Comparator complexity deepens when health systems enter the equation.
Integrated delivery networks often establish internal pathways that:
- Standardize preferred therapies
- Emphasize cost containment
- Align with system contracting strategies
A product may compare favorably against one therapy — but if that therapy isn’t widely used within key systems, the argument weakens.
Evidence that feels compelling nationally may not resonate locally.
Rethinking Comparator Strategy
Forward-looking access teams are moving beyond static comparator assumptions.
They’re asking:
- What does standard of care look like in our highest-priority geographies?
- How do payer formularies differ from system-level pathways?
- Where does competitor penetration diverge from trial assumptions?
This isn’t about changing clinical endpoints.
It’s about aligning value communication with operational reality.
As managed care leaders sharpen their focus on budget predictability and real-world performance, comparator scrutiny increases.
Evidence credibility isn’t only about statistical significance.
It’s about contextual relevance.
If the comparator doesn’t reflect actual practice, even strong data can struggle to persuade.
In today’s environment, the most effective value stories aren’t just clinically sound.
They’re situationally accurate.